Risk of Hospitalization for Severe Hypersensitivity (including Severe Skin Reactions) in Patients with Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Study identifier:CV181-103

ClinicalTrials.gov identifier:NCT01086319

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Comparison of Risk of Hospitalization for Severe Hypersensitivity (including Severe Cutaneous Reactions) Between Patients with Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments

Medical condition

Diabetes Mellitus, Type 2

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

113505

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Aug 2009
Primary Completion Date: 01 Dec 2015
Study Completion Date: 01 Dec 2015

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2016 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Bristol Myers Squibb, University of Pennsylvania

Inclusion and exclusion criteria